香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 國藥一致之主要未經審核財務數據和指標 單位：萬元 幣種：人民幣 | | 本報告期 | 上年同期 | 增減變動幅度 | | --- | --- | --- | --- | | | | | （％） | | 營業總收入 | 3,679,659.84 | 3,778,598.06 | -2.62 | | 營業利潤 | 92,649.65 | 94,886.01 | -2.36 | | 利潤總額 | 91,811.33 | 95,796.89 | -4.16 | | 歸屬於上市公司股東的 | 66,590.73 | 74,348.72 | -10.43 | | 淨利潤 | | | | | 扣除非經常性損益後的 歸屬於上市公司股東的 | 64,286.16 | 71,137.85 | -9 ...

本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年半年度業績快報 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥集 團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公司 2025 年半年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 14 日 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-34 国药集团一致药业股份有限公司 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉 ...

Core Insights - The strategic cooperation agreement between China National Pharmaceutical Group (Sinopharm) and Gilead Sciences aims to enhance the accessibility of innovative antiviral drugs for chronic hepatitis B patients in China [1][2] - Approximately 86 million hepatitis B virus carriers exist in China, accounting for about one-third of the global infected population [1] - The new antiviral drug, Vemlidy (TAF), was launched in China in 2018 and has been included in the national medical insurance directory, making it more affordable for patients [2] Group 1 - The partnership will leverage Sinopharm's extensive network and marketing capabilities to improve the availability of Vemlidy in grassroots markets [1] - Chronic hepatitis B poses significant health risks, including liver cirrhosis and liver cancer, but advancements in antiviral medications have provided safer treatment options with low resistance rates [1] - Gilead Sciences has introduced eight global innovative drugs in China since 2017, focusing on improving drug accessibility through insurance and collaborations [2] Group 2 - Sinopharm's president emphasized the importance of brand, channel, and network advantages in increasing the medical coverage of Vemlidy for more hepatitis B patients [2] - The collaboration marks a new chapter in the ongoing partnership between Sinopharm and Gilead Sciences, which has previously involved a series of import agency collaborations [2]

格隆汇8月12日丨国药控股(01099.HK)公告，将于2025年8月22日(星期五)举行董事会会议，藉以考虑及 批准(其中包括)公司及其附属公司截至2025年6月30日止6个月未经审核中期业绩。 ...

中國，上海 2025 年 8 月 12 日 於本通告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬 先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍 先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 董事會會議通告 國藥控股股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將於 2025 年 8 月 22 日（星期五）舉行董事會會議，藉以考慮及批准（其中包括）本公司及其附屬公司截至 2025 年 6 月 30 日止六個月之未經審核中期業績。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | | 1 RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | | 1 RMB | | 1,341,810,740 | | 2. 股份分類 ...

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme has shown significant growth, with a year-to-date increase of 58.75% [1] Group 1: Index Performance - The index rose by 2.58% to 1088.62 points, with a trading volume of 19.47 billion [1] - Over the past month, the index has increased by 16.48%, and over the last three months, it has risen by 31.51% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (15.03%), JD Health (10.75%), and WuXi AppTec (6.59%) [1] Group 3: Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange [2] - The sector breakdown of the index includes: Pharmaceuticals and Biotechnology Services (33.30%), Medical Services (32.85%), Medical Devices (12.81%), Chemical Drugs (12.34%), and Biological Drugs (8.70%) [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special adjustments made under certain circumstances [2]

Group 1 - The core point of the news is the suspension of procurement activities for two subsidiaries of China National Pharmaceutical Group Corporation (Sinopharm) due to violations of procurement regulations [1][7][9] - The companies involved are Sinopharm (Tianjin) Dongfang Bokang Pharmaceutical Co., Ltd. and Sinopharm Medical Technology (Tianjin) Co., Ltd., both of which are accused of engaging in fraudulent bidding practices [1][7] - The suspension will take effect from June 20, 2025, and will prevent the companies and their associated representatives from participating in military procurement activities during the suspension period [2][9] Group 2 - Sinopharm (Tianjin) Dongfang Bokang Pharmaceutical Co., Ltd. was established on January 6, 1994, and its current legal representative is Liu Zhanwen [13][14] - Sinopharm Medical Technology (Tianjin) Co., Ltd. was established on February 22, 2012, and its current legal representative is Kuang Yu [18] - The legal representatives and major shareholders of both companies are prohibited from participating in military procurement activities during the suspension [2][9]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme Index has shown a recent decline of 0.75%, but it has experienced significant growth over the past months, with a year-to-date increase of 28.05% [1] Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Theme Index closed at 849.54 points with a trading volume of 15.301 billion yuan [1] - Over the past month, the index has increased by 6.08%, and over the last three months, it has risen by 9.80% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (16.26%), JD Health (10.67%), Alibaba Health (6.31%), WuXi AppTec (5.79%), China National Pharmaceutical Group (5.31%), Kingstar BioTech (4.27%), Weigao Group (3.31%), Innovent Biologics (3.06%), CSPC Pharmaceutical Group (2.51%), and MicroPort Scientific Corporation (2.4%) [1] Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

Financial Position - The group's total current assets as of March 31, 2025, amounted to RMB 368.34 billion, compared to RMB 368.03 billion as of December 31, 2024, reflecting a slight increase[6]. - Accounts receivable increased to RMB 221.77 billion from RMB 182.76 billion, indicating a growth of approximately 21.4% year-over-year[6]. - The group's cash and cash equivalents decreased to RMB 45.36 billion from RMB 67.07 billion, representing a decline of about 32.4%[6]. - Inventory levels rose to RMB 66.22 billion, up from RMB 60.94 billion, marking an increase of approximately 8.5%[6]. - Non-current assets totaled RMB 46.74 billion, slightly up from RMB 46.64 billion, showing a marginal growth[6]. - The total assets of the group reached RMB 415.08 billion, compared to RMB 392.67 billion in the previous period, reflecting an increase of approximately 5.7%[6]. - Total liabilities as of March 31, 2025, amounted to RMB 285.93 billion, an increase of 7.83% from RMB 265.76 billion as of December 31, 2024[7]. - Current liabilities totaled RMB 274.03 billion, up from RMB 250.31 billion, indicating a significant increase in short-term financial obligations[7]. - Non-current liabilities decreased to RMB 11.90 billion from RMB 15.45 billion, suggesting a reduction in long-term debt commitments[7]. - The company's total equity reached RMB 129.16 billion, an increase from RMB 126.91 billion, reflecting a positive trend in shareholder equity[7]. Revenue and Profitability - Total operating revenue for the three months ended March 31, 2025, was RMB 141.66 billion, a decrease of 3.67% from RMB 147.27 billion for the same period in 2024[8]. - Net profit for the three months ended March 31, 2025, was RMB 2.26 billion, compared to RMB 2.40 billion in the previous year, indicating a decline of 5.83%[9]. - The company reported a basic and diluted earnings per share of RMB 0.47 for the three months ended March 31, 2025, compared to RMB 0.46 for the same period in 2024[9]. - Total operating costs for the same period were RMB 138.05 billion, down from RMB 143.49 billion, reflecting a cost reduction strategy[8]. - The total operating revenue for the three months ended March 31, 2025, was RMB 5,213,357,504.88, an increase of 6.1% compared to RMB 4,912,928,587.87 for the same period in 2024[18]. - Net profit for the same period was RMB 271,526,239.09, significantly up from RMB 48,414,009.21 in 2024, representing a growth of 461.5%[18]. - Operating profit increased to RMB 281,267,703.10 from RMB 49,745,649.99, marking a rise of 465.5% year-over-year[18]. - The total operating costs for the period were RMB 5,153,579,593.46, an increase from RMB 4,904,594,485.93 in 2024[18]. Cash Flow - Operating cash flow for the three months ended March 31, 2025, was a net outflow of RMB 34.28 billion, an improvement from a net outflow of RMB 47.48 billion for the same period in 2024, representing a 27.5% reduction in cash outflow[10]. - Cash flow from operating activities showed a net outflow of RMB 2,259,793,996.48, compared to a net outflow of RMB 1,912,528,692.92 in the previous year[21]. - Cash flow from investing activities generated a net inflow of RMB 969,545,995.42, up from RMB 407,324,780.59 in 2024[21]. - Cash inflow from financing activities for the three months ended March 31, 2025, was RMB 32.59 billion, a decrease of 20.9% from RMB 41.22 billion in 2024[11]. - The company's net cash flow from financing activities was RMB 12.88 billion for the three months ended March 31, 2025, down 41.5% from RMB 22.15 billion in 2024[11]. - Cash flow from financing activities resulted in a net outflow of RMB 14,237,506,923.58, compared to RMB 17,134,426,936.48 in the previous year[22]. Investments and Strategic Focus - The group has ongoing investments in fixed assets, with a total of RMB 10.52 billion as of March 31, 2025[6]. - The group continues to focus on expanding its market presence and enhancing its product offerings through strategic investments and partnerships[6]. - The company reported a significant increase in investment income, reaching RMB 230,253,895.71, compared to RMB 53,504,018.73 in the same period last year[18]. - The company reported an investment income of RMB 222.21 million, up from RMB 150.12 million, highlighting improved performance in investment activities[8]. - Research and development expenses for the three months were RMB 63.26 million, down from RMB 71.13 million, indicating a potential shift in investment strategy[8]. Inventory and Asset Management - The group reported a significant increase in prepayments, which rose to RMB 7.86 billion from RMB 6.80 billion, indicating a growth of about 15.6%[6]. - The group's goodwill remained stable at approximately RMB 6.20 billion, showing minimal change from the previous period[6]. - The company reported a total inventory of RMB 1.25 billion as of March 31, 2025, up from RMB 1.05 billion at the end of 2024, indicating a 19.3% increase[12]. - The company's long-term borrowings decreased to RMB 1.49 billion as of March 31, 2025, from RMB 4.65 billion at the end of 2024, a significant reduction of 68.0%[15]. - Current liabilities decreased to RMB 43.30 billion as of March 31, 2025, from RMB 55.42 billion at the end of 2024, a reduction of 21.9%[15]. - The total equity increased to RMB 33.57 billion as of March 31, 2025, compared to RMB 33.29 billion at the end of 2024, showing a growth of 0.8%[16]. - Cash and cash equivalents decreased to RMB 33.53 billion as of March 31, 2025, from RMB 38.74 billion at the end of 2024, a decline of 13.4%[11]. - The cash and cash equivalents at the end of the period stood at RMB 14,672,100,199.21, compared to RMB 14,194,374,852.87 at the end of March 2024[22].